Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development

ABSTRACT Chikungunya virus (CHIKV) is an alphavirus which causes chronic and incapacitating arthralgia in humans. Although previous studies have shown that antibodies against the virus are produced during and after infection, the fine specificity of the antibody response against CHIKV is not known. Here, using plasma from patients at different times postinfection, we characterized the antibody response against various proteins of the virus. We have shown that the E2 and E3 glycoproteins and the capsid and nsP3 proteins are targets of the anti-CHIKV antibody response. Moreover, we have identified the different regions in these proteins which contain the linear epitopes recognized by the anti-CHIKV antibodies and determined their structural localization. Data also illustrated the effect of a single K252Q amino acid change at the E2 glycoprotein that was able to influence antibody binding and interaction between the antibodies and epitope because of the changes of epitope-antibody binding capacity. This study provides important knowledge that will not only aid in the understanding of the immune response to CHIKV infection but also provide new knowledge in the design of modern vaccine development. Furthermore, these pathogen-specific epitopes could be used for future seroepidemiological studies that will unravel the molecular mechanisms of human immunity and protection from CHIKV disease.

[1]  Sudhir V. Shah,et al.  Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  S. Higgs,et al.  Epistatic Roles of E2 Glycoprotein Mutations in Adaption of Chikungunya Virus to Aedes Albopictus and Ae. Aegypti Mosquitoes , 2009, PloS one.

[3]  L. Rénia,et al.  Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection , 2012, The Journal of infectious diseases.

[4]  Y. Leo,et al.  Clinical features and epidemiology of chikungunya infection in Singapore. , 2009, Singapore medical journal.

[5]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[6]  K. Suwannakarn,et al.  Molecular genome tracking of East, Central and South African genotype of Chikungunya virus in South-east Asia between 2006 and 2009. , 2011, Asian Pacific journal of tropical medicine.

[7]  P. Gasque,et al.  Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  P. Vidalain,et al.  Mapping of Chikungunya Virus Interactions with Host Proteins Identified nsP2 as a Highly Connected Viral Component , 2012, Journal of Virology.

[9]  K. Praianantathavorn,et al.  Clinical and molecular characterization of chikungunya virus in South Thailand. , 2009, Japanese journal of infectious diseases.

[10]  D. Norwood,et al.  Antibody to the E3 Glycoprotein Protects Mice against Lethal Venezuelan Equine Encephalitis Virus Infection , 2010, Journal of Virology.

[11]  K. Chua,et al.  Chikungunya infection--an emerging disease in Malaysia. , 2001, The Southeast Asian journal of tropical medicine and public health.

[12]  W. Lumsden.  An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. II. General description and epidemiology. , 1955, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  M. Peiris,et al.  Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro , 2006, Vaccine.

[14]  N. Seidah,et al.  Inhibition of Chikungunya Virus Infection in Cultured Human Muscle Cells by Furin Inhibitors , 2008, Journal of Biological Chemistry.

[15]  M C ROBINSON,et al.  An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. , 1955, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[16]  Y. Leo,et al.  Chikungunya fever in Singapore: acute clinical and laboratory features, and factors associated with persistent arthralgia. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  Esther G. L. Koh,et al.  Chikungunya Virus Neutralization Antigens and Direct Cell-to-Cell Transmission Are Revealed by Human Antibody-Escape Mutants , 2011, PLoS pathogens.

[18]  J. Tong,et al.  Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein , 2012, EMBO molecular medicine.

[19]  P. Gage,et al.  Alphavirus 6K Proteins Form Ion Channels* , 2002, The Journal of Biological Chemistry.

[20]  T. Ahola,et al.  The Effects of Palmitoylation on Membrane Association of Semliki Forest Virus RNA Capping Enzyme* , 1996, The Journal of Biological Chemistry.

[21]  P. Desprès,et al.  Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency , 2011, The Journal of Immunology.

[22]  P. Auvinen,et al.  Effects of Palmitoylation of Replicase Protein nsP1 on Alphavirus Infection , 2000, Journal of Virology.

[23]  S. Mukhopadhyay,et al.  Role of Conserved Cysteines in the Alphavirus E3 Protein , 2008, Journal of Virology.

[24]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[25]  J. Roehrig,et al.  The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. , 1985, Virology.

[26]  Frank Kunst,et al.  Genome Microevolution of Chikungunya Viruses Causing the Indian Ocean Outbreak , 2006, PLoS medicine.

[27]  G. Nabel,et al.  A Specific Domain of the Chikungunya Virus E2 Protein Regulates Particle Formation in Human Cells: Implications for Alphavirus Vaccine Design , 2012, Journal of Virology.

[28]  J. H. Strauss,et al.  Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants , 1991, Journal of virology.

[29]  Pamela J. Glass,et al.  Chikungunya Virus Strains, Reunion Island Outbreak , 2006, Emerging infectious diseases.

[30]  Nicolas Gangneux,et al.  Prophylaxis and Therapy for Chikungunya Virus Infection , 2009, The Journal of infectious diseases.

[31]  L. Ng,et al.  Host response to Chikungunya virus and perspectives for immune-based therapies , 2011 .

[32]  S. Larrieu,et al.  A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. , 2007, The American journal of tropical medicine and hygiene.

[33]  P. Auvinen,et al.  Semliki Forest virus mRNA capping enzyme requires association with anionic membrane phospholipids for activity , 1999, The EMBO journal.

[34]  K. Pavri.  Disappearance of Chikungunya virus from India and South East Asia. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[35]  J. H. Strauss,et al.  The Alphaviruses: Gene Expression, Replication, and Evolution , 1994, Microbiological reviews.

[36]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[37]  R. Kuhn,et al.  A structural and functional perspective of alphavirus replication and assembly. , 2009, Future microbiology.

[38]  T. Bentley,et al.  Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. , 1992, Immunology letters.

[39]  Andrew E Firth,et al.  Discovery of frameshifting in Alphavirus 6K resolves a 20-year enigma , 2008, Virology Journal.

[40]  J. Boutin,et al.  Clinical burden of chikungunya virus infection. , 2008, The Lancet. Infectious diseases.

[41]  Young Do Kwon,et al.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.

[42]  Yang Zhang,et al.  I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.

[43]  D. Munasinghe,et al.  An epidemic of dengue-like fever in Ceylon (chikungunya--a clinical and haematological study. , 1966, The Ceylon medical journal.

[44]  D. Beasley,et al.  Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system. , 1997, The Journal of general virology.

[45]  A. Powers,et al.  Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. , 2007, The Journal of general virology.

[46]  P. Wingfield,et al.  Characterization of a Conformational Epitope on Hepatitis B Virus Core Antigen and Quasiequivalent Variations in Antibody Binding , 2003, Journal of Virology.

[47]  Monica Chan,et al.  Active Infection of Human Blood Monocytes by Chikungunya Virus Triggers an Innate Immune Response , 2010, The Journal of Immunology.